Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $43.3 million.

  • Day One Biopharmaceuticals' Cash & Equivalents fell 8976.33% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year decrease of 8976.33%. This contributed to the annual value of $125.0 million for FY2024, which is 4585.07% down from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Cash & Equivalents stood at $43.3 million for Q3 2025, which was down 8976.33% from $35.6 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Cash & Equivalents high stood at $422.8 million for Q3 2024, and its period low was $33.4 million during Q1 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' median Cash & Equivalents value was $189.2 million (recorded in 2023), while the average stood at $182.5 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 44881.67% in 2024, then crashed by 8976.33% in 2025.
  • Day One Biopharmaceuticals' Cash & Equivalents (Quarter) stood at $85.3 million in 2022, then surged by 170.68% to $230.8 million in 2023, then plummeted by 45.85% to $125.0 million in 2024, then plummeted by 65.37% to $43.3 million in 2025.
  • Its Cash & Equivalents was $43.3 million in Q3 2025, compared to $35.6 million in Q2 2025 and $33.4 million in Q1 2025.